FindTrial
Sign In

A double-blind, placebo controlled study to assess the effects of early intervention and/or treatment with epoetin alfa on anaemia in cancer patients receiving non-platinum containing chemotherapy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN98318971
Enrollment
Unknown
Registered
2002-08-19
Start date
2003-01-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anaemia Haematological Disorders Anaemia in chronic diseases classified elsewhere

Interventions

Patients are randomised to one of two treatment arms: 1. Arm A: Patients receive 150 IU/Kg of Epoetin alpha 2. Arm B: Patients receive matching placebo Epoetin alpha or placebo is given subcutaneous

Sponsors

Janssen-Cilag Ltd (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Diagnosis of non-myeloid malignancy, which requires non-platinum containing chemotherapy 2. Predicted chemotherapy of 12 to 24 weeks (three to six cycles) duration 3. Performance score zero to three 4. Life expectancy of more than six months 5. Aged over 18 years 6. Patients with acute leukaemia are excluded 7. No myeloablative chemotherapy 8. No uncontrolled hypertension 9. No evidence of untreated iron, folate or vitamin B12 deficiency

Exclusion criteria

Exclusion criteria: Does not comply with the above inclusion criteria

Design outcomes

Primary

MeasureTime frame
Not provided at time of registration—

Secondary

MeasureTime frame
Not provided at time of registration—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026